Juraj Sokol, Juraj Chudej, Zuzana Jedináková, Adam Butkovský, Matej Hrnčár, Andrej Rosík, Peter Kubisz, Ján Staško
Multiple myeloma is an incurable malignancy caused by neoplastic proliferation of a clone of malignant plasma cells,
although patient survival has increased with the availability of novel agents. Both multiple myeloma and its therapies
often affect the renal, immune, skeletal, hematologic, and nervous systems. The newer treatment options have changed
the natural history for patients with myeloma; treatment-related toxicities are always of concern. Therefore, adjunctive
treatment is considered an essential part of myeloma therapy.